References
1. WHO Coronavirus (COVID-19) Dashboard. URL: https:covid19.who.int
2. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. Nat. Microbiol. 2020; 5: 536–44. DOI: https://doi.org/10.1038/s41564-020-0695-z
3. Xu Z., Shi L., Wang Y., Zhang J., et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir. Med. 2020; 8: 420–2. DOI: https://doi.org/10.1016/S2213-2600(20)30076-X
4. Nile S.H., Nile A., Qiu J., Li L., Jia X., Kai G. COVID-19: pathogenesis, cytokine storm and therapeutic potential of interferons. Cytokine Growth Factor Rev. 2020; 53: 66–70. DOI: https://doi.org/10.1016/j.cytogfr.2020.05.002
5. Blanco-Melo D., Nilsson-Payant B.E., Liu W.C., Uhl S., et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell. 2020; 181 (5): 1036–45.e9. DOI: https://doi.org/10.1016/j.cell.2020.04.026
6. Zhou Z., Ren L., Zhang L., Zhong J., et al. Heightened innate immune responses in the respiratory tract of COVID-19 patients. Cell Host Microbe. 2020; 27 (6): 883–90.e2. DOI: https://doi.org/10.1016/j.chom.2020.04.017
7. Gao Y., Wang C., Kang K., Peng Y., et al. Cytokine storm may not be the chief culprit for the deterioration of COVID-19. Viral Immunol. 2021; 34 (5): 336–41. DOI: http://doi.org/10.1089/vim.2020.0243
8. King C., Sprent J. Dual nature of type I interferons in SARS-CoV-2-induced inflammation. Trends Immunol. 2021; 42 (4): 312–22. DOI: https://doi.org/10.1016/j.it.2021.02.003
9. Schreiber G. The role of type I interferons in the pathogenesis and treatment of COVID-19. Front. Immunol. 2020; 11: 595739. DOI: https://doi.org/10.3389/fimmu.2020.595739
10. Ershov F.I., Narovlyansky A.N. Interferons and interferon inducers. Chapter 6. P. 123–147. In: Khaitov R.M., Ataullakhanov R.I., Shulzhenko A.E. (eds). Immunotherapy: a guide for doctors. 2nd ed. revised and additional. Moscow: GEOTAR-Media, 2018: 768 p. ISBN: 978-5-9704-4378-1. (in Russian)
11. Zhang X., Brann T.W., Zhou M., Yang J., et al. Cutting edge: Ku70 is a novel cytosolic DNA sensor that induces type III rather than type I IFN. J. Immunol. 2011; 186 (8): 4541–5. DOI: https://doi.org/10.4049/jimmunol.1003389
12. McBride K.M., Banninger G., McDonald C., Reich N.C. Regulated nuclear import of the STAT1 transcription factor by direct binding of importin-alpha. EMBO J. 2002; 21 (7): 1754–63. DOI: https://doi.org/10.1093/emboj/21.7.1754
13. Ershov F.I. Antiviral drugs. 2nd ed. Moscow: GEOTAR-Media, 2006: 312 p. ISBN: 5-9704-0164-1. (in Russian)
14. Ershov F.I., Kiselev O.I. Interferons and their inducers (from molecules to drugs). Moscow: GEOTAR-Media, 2005: 356 p. ISBN: 5-9704-0060-2. (in Russian)
15. Narovlyansky A.N. Classification and mechanisms of interferon action. In: F.I. Ershov (ed.). Interferon is 50 years old. Anniversary collection. Moscow, 2007: 44–50. ISBN: 978-5-903557-04-2. (in Russian)
16. Interferon-2011. Collection of scientific articles. In: F.I. Ershov, A.N. Narovlyansky (eds). Moscow, 2012: 512 p. ISBN: 978-5-9902840-2-9. (in Russian)
17. Мarsili G., Perrotti E., Remoli A.L., Acchioni C., et al. IFN regulatory factors and antiviral innate immunity: how viruses can get better. J. Interferon Cytokine Res. 2016; 36 (7): 414–32. DOI: https://doi.org/10.1089/jir.2016.0002
18. González-Navajas J.M., Li J., David M., Raz E. Immunomodulatory functions of type I interferons. Nat. Rev. Immunol. 2012; 12 (2): 125–35. DOI: https://doi.org/10.1038/nri3133
19. Kikkert M. Innate immune evasion by human respiratory RNA viruses. J. Innate Immun. 2020; 12 (1): 4–20. DOI: https://doi.org/10.1159/000503030
20. Kopecky-Bromberg S., Martinez-Sobrido L., Frieman M., Baric R., Palese P. Severe acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6, and nucleocapsid proteins function as interferon antagonists. J. Virol. 2007; 81 (2): 548–57. DOI: https://doi.org/10.1128/JVI.01782-06
21. Kumar S., Nyodu R., Maurya V.K., Saxena S.K. Host immune response and immunobiology of human SARS-CoV-2 infection. In: Coronavirus Disease 2019 (COVID-19), Medical Virology: from Pathogenesis to Disease Control. Saxena S.K. (ed.). Singapore : Springer Nature, 2020: 43–53. DOI: https://doi.org/10.1007/978-981-15-4814-7_5
22. Felsenstein S., Herbert J.A., McNamara P.S., Hedrich C.M. COVID-19: immunology and treatment options. Clin. Immunol. 2020; 215: 108448. DOI: https://doi.org/10.1016/j.clim.2020.108448
23. Bahari Z., Jangravi Z., Ghoshooni H., et al. Pharmacological mechanism of immunomodulatory agents for the treatment of severe cases of COVID-19 infection. Inflamm. Res. 2021; 70: 389–405. DOI: https://doi.org/10.1007/s00011-021-01445-2
24. Channappanavar R., Fehr A.R., Vijay R., Mack M., et al. Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice. Cell Host Microbe. 2016; 19 (2): 181–93. DOI: https://doi.org/10.1016/j.chom.2016.01.007 PMID: 26867177; PMCID: PMC4752723.
25. Catanzaro M., Fagiani F., Racchi M., Corsini E., et al. Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2. Signal Transduct. Target. Ther. 2020; 5 (1): 84. DOI: https://doi.org/10.1038/s41392-020-0191-1 PMID: 32467561; PMCID: PMC7255975.
26. Xia H., Shi P.-Y. Antagonism of type I interferon by severe acute respiratory syndrome coronavirus 2. J. Interferon Cytokine Res. 2020; 40 (12): 543–8. DOI: https://doi.org/10.1089/jir.2020.0214
27. Lee J.G., Huang W., Lee H., et al. Characterization of SARS-CoV-2 proteins reveals Orf6 pathogenicity, subcellular localization, host interactions and attenuation by Selinexor. Cell Biosci. 2021; 11: 58. DOI: https://doi.org/10.1186/s13578-021-00568-7
28. Dhakal S., Macreadie I. Genes of SARS-CoV-2 and emerging variants. Microbiol. Aust. 2021; 42 (1): 10–2. DOI: https://doi.org/10.1071/MA21004
29. Xia H., Cao Z., Xie X., Zhang X., et al. Evasion of type-I interferon by SARS-CoV-2. Cell Rep. 2020; 33 (1): 108234. DOI: https://doi.org/10.1016/j.celrep.2020.108234
30. Lei X., Dong X., Ma R., Wang W., et al. Activation and evasion of type I interferon responses by SARS-CoV-2. Nat. Commun. 2020; 11: 3810. DOI: https://doi.org/10.1038/s41467-020-17665-9
31. Rabouw H.H., Langereis M.A., Knaap R.C.M., Dalebout T.J., et al. Middle East respiratory coronavirus accessory protein 4a inhibits PKR-mediated antiviral stress responses. PLoS Pathog. 2016; 12 (10): e1005982. DOI: https://doi.org/10.1371/journal.ppat.1005982
32. Jiang H.W., Zhang H.N., Meng Q.F., Xie J., et al. SARS-CoV-2 Orf9b suppresses type I interferon responses by targeting TOM70. Cell. Mol. Immunol. 2020; 17 (9): 998–1000. DOI: https://doi.org/10.1038/s41423-020-0514-8
33. Israelow B., Song E., Mao T., Lu P., et al. Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling. J. Exp. Med. 2020; 217 (12): e20201241. DOI: https://doi.org/10.1084/jem.20201241
34. García-Sastre A. Ten strategies of interferon evasion by viruses. Cell Host Microbe. 2017; 22 (2): 176–84. DOI: https://doi.org/10.1016/j.chom.2017.07.012 PMID: 28799903; PMCID: PMC5576560.
35. Stertz S., Reichelt M., Spiegel M., Kuri T., et al. The intracellular sites of early replication and budding of SARS-coronavirus. Virology. 2007; 361 (2): 304–15. DOI: https://doi.org/10.1016/j.virol.2006.11.027 Epub 2007 Jan 8. PMID: 17210170; PMCID: PMC7103305.
36. Daffis S., Szretter K.J., Schriewer J., Li J., et al. 2’-O methylation of the viral mRNA cap evades host restriction by IFIT family members. Nature. 2010; 468 (7322): 452–56. DOI: https://doi.org/10.1038/nature09489 PMID: 21085181; PMCID: PMC3058805.
37. Mantlo E., Bukreyeva N., Maruyama J., Paessler S., Huang C. Antiviral activities of type I interferons to SARS-CoV-2 infection. Antiviral Res. 2020; 179: 104811. DOI: https://doi.org/10.1016/j.antiviral.2020.104811 Epub 2020 Apr 29. PMID: 32360182; PMCID: PMC7188648.
38. Schroeder S., Pott F., Niemeyer D., Veith T., et al. Interferon antagonism by SARS-CoV-2: a functional study using reverse genetics. Lancet Microbe. 2021; 2 (5): e210–8. DOI: https://doi.org/10.1016/S2666-5247(21)00027-6 URL: https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(21)00027-6/fulltext
39. Suryawanshi R.K., Koganti R., Agelidis A., Patil C.D., Shukla D. Dysregulation of cell signaling by SARS-CoV-2. Trends Microbiol. 2021; 29 (3): 224–37. DOI: https://doi.org/10.1016/j.tim.2020.12.007
40. Rodriguez-Morales A.J., Cardona-Ospina J.A., Gutierrez-Ocampo E., Villamizar-Pena R., et al. Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis. Travel Med. Infect. Dis. 2020; 34: 101623. DOI: https://doi.org/10.1016/j.tmaid.2020.101623
41. Wei L.L., Wang W.J., Chen D.X., Xu B. Dysregulation of the immune response affects the outcome of critical COVID-19 patients. J. Med. Virol. 2020; 92 (11): 2768–76. DOI: https://doi.org/10.1002/jmv.26181 PMID: 32543740; PMCID: PMC7323247.
42. Daamen A.R., Bachali P., Owen K.A., Kingsmore K.M., et al. Comprehensive transcriptomic analysis of COVID-19 blood, lung, and airway. Sci. Rep. 2021; 11 (1): 7052. DOI: https://doi.org/10.1038/s41598-021-86002-x PMID: 33782412; PMCID: PMC8007747.
43. Martin-Sancho L., Lewinski M.K., Pache L. Functional landscape of SARS-CoV-2 cellular restriction. Mol. Cells. 2021; 81 (12): 2656–68.E8. DOI: https://doi.org/10.1016/j.molcel.2021.04.008
44. Faure E., Poissy J., Goffard A., Fournier C., et al. Distinct immune response in two MERS-CoV-infected patients: can we go from bench to bedside? PLoS One. 2014; 9 (2): e88716. DOI: https://doi.org/10.1371/journal.pone.0088716 PMID: 24551142; PMCID: PMC3925152.
45. Channappanavar R., Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin. Immunopathol. 2017; 39 (5): 529–39. DOI: https://doi.org/10.1007/s00281-017-0629-x
46. Huang K.J., Su I.J., Theron M., Wu Y.C., et al. An interferon-gamma-related cytokine storm in SARS patients. J. Med. Virol. 2005; 75 (2): 185–94. DOI: https://doi.org/10.1002/jmv.20255 PMID: 15602737; PMCID: PMC7166886.
47. Cameron M.J., Ran L., Xu L., Danesh A., et al. Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome. J. Virol. 2007; 81 (16): 8692–706. DOI: https://doi.org/10.1128/JVI.00527-07 PMID: 17537853; PMCID: PMC1951379.
48. Hadjadj J., Yatim N., Barnabei L., Corneau A., et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 2020; 369: 718–24. DOI: https://doi.org/10.1126/science.abc6027
49. Mosser D.M., Hamidzadeh K., Goncalves R. Macrophages and the maintenance of homeostasis. Cell. Mol. Immunol. 2021; 18: 579–87. DOI: https://doi.org/10.1038/s41423-020-00541-3
50. Diao B., Wang C., Tan Y., Chen X., et al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Front. Immunol. 2020; 11: 827. DOI: https://doi.org/10.3389/fimmu.2020.00827
51. Zhang Q., Bastard P., Liu Z., Le Pen J., et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020; 370 (6515): eabd4570. DOI: https://doi.org/10.1126/science.abd4570 PMID: 32972995; PMCID: PMC7857407.
52. Bastard P., Rosen L.B., Zhang Q., Michailidis E., et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020; 370 (6515): eabd4585. DOI: https://doi.org/10.1126/science.abd4585 PMID: 32972996; PMCID: PMC7857397.
53. Lucas C., Wong P., Klein J., Castro T.B.R., et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature. 2020; 584 (7821): 463–9. DOI: https://doi.org/10.1038/s41586-020-2588-y PMID: 32717743; PMCID: PMC7477538.
54. Agrawal A. Mechanisms and implications of age-associated impaired innate interferon secretion by dendritic cells: a mini-review. Gerontology. 2013; 59 (5): 421–6. DOI: https://doi.org/10.1159/000350536 PMID: 23615484.
55. Sun S., Zhang X., Tough D.F., Sprent J. Type I interferon-mediated stimulation of T cells by CpG DNA. J. Exp. Med. 1998; 188 (12): 2335–42. DOI: https://doi.org/10.1084/jem.188.12.2335 PMID: 9858519; PMCID: PMC2212431.
56. Moore J.B., June C.H. Cytokine release syndrome in severe COVID-19. Science. 2020; 368 (6490): 473–4. DOI: https://doi.org/10.1126/science.abb8925 PMID: 32303591.
57. Li S., Zhang Y., Guan Z., Li H., et al. SARS-CoV-2 triggers inflammatory responses and cell death through caspase-8 activation. Signal Transduct. Target. Ther. 2020; 5 (1): 235. DOI: https://doi.org/10.1038/s41392-020-00334-0 PMID: 33037188; PMCID: PMC7545816.
58. Yang M. Cell pyroptosis, a potential pathogenic mechanism of 2019-nCoV infection. SSRN. 2020. DOI: https://doi.org/10.2139/ssrn.3527420 URL: https://ssrn.com/abstract=3527420
59. Velazquez-Salinas L., Verdugo-Rodriguez A., Rodriguez L.L., Borca M.V. The role of interleukin 6 during viral infections. Front. Microbiol. 2019; 10: 1057. DOI: https://doi.org/10.3389/fmicb.2019.01057 PMID: 31134045; PMCID: PMC6524401.
60. Cho J.H., Kim H.O., Webster K., Palendira M., et al. Calcineurin-dependent negative regulation of CD94/NKG2A expression on naive CD8+ T cells. Blood. 2011; 118 (1): 116–28. DOI: https://doi.org/10.1182/blood-2010-11-317396 PMID: 21540458.
61. Wu S.C., Arthur C.M., Wang J., Verkerke H., et al. The SARS-CoV-2 receptor-binding domain preferentially recognizes blood group A. Blood Adv. 2021; 5 (5): 1305–9. DOI: https://doi.org/10.1182/bloodadvances.2020003259 PMID: 33656534; PMCID: PMC7929867.
62. Wu B.B., Gu D.Z., Yu J.N., Yang J., Shen W.Q. Association between ABO blood groups and COVID-19 infection, severity and demise: a systematic review and meta-analysis. Infect. Genet. Evol. 2020; 84: 104485. DOI: https://doi.org/10.1016/j.meegid.2020.104485 PMID: 32739464; PMCID: PMC7391292.
63. Ershov F.I., Gotovtseva E.L., Nosik N.N. Interferon status is normal. Immunologiya. 1986; 3: 52–4. (in Russian)
64. About adaptation of the causative agent of COVID-19 to the human population. Federal’naya sluzhba po nadzoru v sfere zashchity prav potrebiteley i blagopoluchiya cheloveka, 2021. URL: https://www.rospotrebnadzor.ru/about/info/predpr/news_predpr.php?ELEMENT_ID=15426 (in Russian)